EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Eurneffy (epinephrine), the first medicine to be taken through the nose for the emergency treatment of allergic reactions (anaphylaxis).
According to the European Academy of Allergy and Clinical Immunology (EAACI), allergy is the most widespread chronic disorder in Europe, with 150 million Europeans affected in 2015. Around 20% of people suffering from severe allergic conditions live in fear every day of an anaphylactic shock or of dying from an allergic reaction…
